Utility of interim and end-of-treatment PET/CT in XXXX : A review of 124 @entity1 .

@entity1 @entity706 @entity3012 @entity3726 @entity3191 @entity784 @entity2108
According to the updated guidelines for imaging in lymphoma, 18F-FDG positron emission tomography/computed tomography (PET/CT) is recommended for staging and evaluation of treatment response in FDG-avid @entity706 . The purpose of the study was to evaluate the utility of PET/CT in nodal @entity3191 ( @entity3191 ). @entity1 with newly diagnosed @entity3191 ( @entity3191 , @entity2108 , or angioimmunoblastic @entity784 ) seen at five Danish hematology centers during the period 2006 to 2012 were included, if they had been pretherapeutically staged with PET/CT. Medical records were reviewed for baseline clinical and follow-up information. Staging, interim (I-PET), and end-of-treatment PET/CT (E-PET) studies were centrally reviewed, and reported using the Deauville 5-point score (DS). A total of 124 @entity1 fulfilled the inclusion criteria. The median age was 58 years, and 88% received @entity3726 / @entity3726 -like therapy. Five years PFS and @entity3012 of the study population was 36.8% (95% CI 27.3-46.4) and 49.7% (95% CI 38.9-59.6), respectively. The presence of PET/CT-ascertained lung and/or liver involvement was associated with a worse outcome. The sensitivity of PET/CT for detecting biopsy-defined bone marrow involvement was only 18% (95% CI 4-43). An interim DS >3 was not prognostic for worse @entity3012 and PFS among @entity3726 / @entity3726 -like treated @entity1 in uni- or multivariate analyses. A DS >3 after treatment predicted a worse prognosis. In conclusion, I-PET was not predictive of outcome in @entity3726 / @entity3726 -like treated @entity3191 @entity1 when using the DS. Prospective studies are needed to determine the optimal use of PET/CT in @entity3191 including the role of quantitative PET/CT analysis.
